• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

表达谱扰动改变人源肝细胞系中的脂代谢。

Perturbation of Expression Alters Lipid Metabolism in a Human Liver Cell Line.

机构信息

Division of Gastroenterology and Hepatology, University of Michigan Health System, Ann Arbor, MI 48109, USA.

Department of Computational Medicine and Bioinformatics, University of Michigan Medical School, Ann Arbor, MI 48109, USA.

出版信息

Int J Mol Sci. 2021 Sep 9;22(18):9758. doi: 10.3390/ijms22189758.

DOI:10.3390/ijms22189758
PMID:34575933
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8471112/
Abstract

Non-alcoholic fatty liver disease (NAFLD) is caused by excess lipid accumulation in hepatocytes. Genome-wide association studies have identified a strong association of NAFLD with non-synonymous E167K amino acid mutation in the transmembrane 6 superfamily member 2 (TM6SF2) protein. The E167K mutation reduces TM6SF2 stability, and its carriers display increased hepatic lipids and lower serum triglycerides. However, the effects of TM6SF2 on hepatic lipid metabolism are not completely understood. We overexpressed wild-type or E167K variant of or knocked down expression in lipid-treated Huh-7 cells and used untargeted lipidomic analysis, RNAseq transcriptome analysis, and fluorescent imaging to determine changes in hepatic lipid metabolism. Both knockdown and E167K overexpression increased hepatic lipid accumulation, while wild-type overexpression decreased acylglyceride levels. We also observed lipid chain remodeling for acylglycerides by knockdown, leading to a relative increase in species with shorter, more saturated side chains. RNA-sequencing revealed differential expression of several lipid metabolizing genes, including genes belonging to AKR1 family and lipases, primarily in cells with knockdown. Taken together, our data show that overexpression of gene or its loss-of-function changes hepatic lipid species composition and expression of lipid metabolizing genes. Additionally, our data further confirms a loss-of-function effect for the E167K variant.

摘要

非酒精性脂肪性肝病 (NAFLD) 是由肝细胞内脂质蓄积过多引起的。全基因组关联研究发现,NAFLD 与跨膜 6 超家族成员 2(TM6SF2)蛋白中 E167K 氨基酸的非同义突变有很强的相关性。E167K 突变降低了 TM6SF2 的稳定性,其携带者表现出肝内脂质增加和血清甘油三酯降低。然而,TM6SF2 对肝内脂质代谢的影响尚不完全清楚。我们在脂质处理的 Huh-7 细胞中转染野生型或 E167K 突变型或敲低 表达,并进行非靶向脂质组学分析、RNAseq 转录组分析和荧光成像,以确定肝内脂质代谢的变化。 敲低和 E167K 过表达均增加肝内脂质蓄积,而野生型过表达则降低酰基甘油水平。我们还观察到 敲低导致酰基甘油的脂质链重塑,导致短链、更饱和的侧链相对增加。RNA-seq 揭示了几种脂质代谢基因的差异表达,包括 AKR1 家族和脂肪酶的基因,主要在 敲低的细胞中。综上所述,我们的数据表明, 基因的过表达或功能丧失会改变肝内脂质种类组成和脂质代谢基因的表达。此外,我们的数据进一步证实了 E167K 变体的功能丧失效应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b21/8471112/95f1219d811c/ijms-22-09758-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b21/8471112/b98c691484f1/ijms-22-09758-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b21/8471112/5b977a03b276/ijms-22-09758-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b21/8471112/987089478dc3/ijms-22-09758-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b21/8471112/95f1219d811c/ijms-22-09758-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b21/8471112/b98c691484f1/ijms-22-09758-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b21/8471112/5b977a03b276/ijms-22-09758-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b21/8471112/987089478dc3/ijms-22-09758-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b21/8471112/95f1219d811c/ijms-22-09758-g004.jpg

相似文献

1
Perturbation of Expression Alters Lipid Metabolism in a Human Liver Cell Line.表达谱扰动改变人源肝细胞系中的脂代谢。
Int J Mol Sci. 2021 Sep 9;22(18):9758. doi: 10.3390/ijms22189758.
2
Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD.载有 TM6SF2 E167K 变异的非酒精性脂肪性肝病患者,多不饱和脂肪酸对肝脏脂质合成的影响受损。
J Hepatol. 2017 Jul;67(1):128-136. doi: 10.1016/j.jhep.2017.02.014. Epub 2017 Feb 22.
3
Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans.TM6SF2 E167K对人类肝脏脂质及极低密度脂蛋白代谢的影响。
JCI Insight. 2020 Dec 17;5(24):144079. doi: 10.1172/jci.insight.144079.
4
Disruption of the ERLIN-TM6SF2-APOB complex destabilizes APOB and contributes to non-alcoholic fatty liver disease.ERLIN-TM6SF2-APOB 复合物的破坏使 APOB 不稳定,并导致非酒精性脂肪性肝病。
PLoS Genet. 2020 Aug 10;16(8):e1008955. doi: 10.1371/journal.pgen.1008955. eCollection 2020 Aug.
5
Mechanism and therapeutic strategy of hepatic -deficient non-alcoholic fatty liver diseases and experiments.肝缺失型非酒精性脂肪性肝病的机制和治疗策略及实验研究。
World J Gastroenterol. 2022 Jul 7;28(25):2937-2954. doi: 10.3748/wjg.v28.i25.2937.
6
Independent and joint correlation of PNPLA3 I148M and TM6SF2 E167K variants with the risk of coronary heart disease in patients with non-alcoholic fatty liver disease.载脂蛋白基因 I148M 及 TM6SF2 基因 E167K 变异与非酒精性脂肪性肝病患者冠心病风险的独立及联合相关性。
Lipids Health Dis. 2020 Feb 24;19(1):29. doi: 10.1186/s12944-020-01207-9.
7
Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2.循环三酰甘油特征与 TM6SF2 中的 E167K 变异相关的非酒精性脂肪性肝病患者的胰岛素敏感性。
J Hepatol. 2015 Mar;62(3):657-63. doi: 10.1016/j.jhep.2014.10.010. Epub 2014 Oct 19.
8
Hepatic Tm6sf2 overexpression affects cellular ApoB-trafficking, plasma lipid levels, hepatic steatosis and atherosclerosis.肝脏中Tm6sf2的过表达会影响细胞载脂蛋白B的运输、血浆脂质水平、肝脏脂肪变性和动脉粥样硬化。
Hum Mol Genet. 2017 Jul 15;26(14):2719-2731. doi: 10.1093/hmg/ddx159.
9
Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes.TM6SF2 基因 rs58542926 E167K 变异对病毒和代谢性肝病表型的影响各异。
Hepatology. 2016 Jul;64(1):34-46. doi: 10.1002/hep.28475. Epub 2016 Mar 30.
10
Interaction of TM6SF2 E167K and PNPLA3 I148M variants in NAFLD in northeast China.TM6SF2 E167K 和 PNPLA3 I148M 变异体在东北地区非酒精性脂肪性肝病中的相互作用。
Ann Hepatol. 2019 May-Jun;18(3):456-460. doi: 10.1016/j.aohep.2018.10.005. Epub 2019 Apr 15.

引用本文的文献

1
A Defective Circulating Mitochondrial Bioenergetics Profile Reflects the Hepatic One and Outlines Genetic MASLD.循环线粒体生物能量学特征缺陷反映肝脏特征并勾勒出遗传代谢相关脂肪性肝病。
Antioxidants (Basel). 2025 May 22;14(6):618. doi: 10.3390/antiox14060618.
2
Deep metabolic phenotyping of humans with protein-altering variants in using a genome-first approach.使用基因组优先方法对具有蛋白质改变变体的人类进行深度代谢表型分析。
JHEP Rep. 2024 Oct 11;7(1):101243. doi: 10.1016/j.jhepr.2024.101243. eCollection 2025 Jan.
3
Nicotinate-curcumin improves NASH by inhibiting the AKR1B10/ACCα-mediated triglyceride synthesis.

本文引用的文献

1
Metabolic analysis of early nonalcoholic fatty liver disease in humans using liquid chromatography-mass spectrometry.使用液相色谱 - 质谱联用技术对人类早期非酒精性脂肪性肝病进行代谢分析。
J Transl Med. 2021 Apr 15;19(1):152. doi: 10.1186/s12967-021-02820-7.
2
Liver-Specific Deletion of Mouse Tm6sf2 Promotes Steatosis, Fibrosis, and Hepatocellular Cancer.肝特异性敲除小鼠 Tm6sf2 促进脂肪变性、纤维化和肝细胞癌。
Hepatology. 2021 Sep;74(3):1203-1219. doi: 10.1002/hep.31771. Epub 2021 May 22.
3
ER stress-induced adipocytes secrete-aldo-keto reductase 1B7-containing exosomes that cause nonalcoholic steatohepatitis in mice.
烟酰胺-姜黄素通过抑制 AKR1B10/ACCα 介导的甘油三酯合成改善 NASH。
Lipids Health Dis. 2024 Jun 27;23(1):201. doi: 10.1186/s12944-024-02162-5.
内质网应激诱导的脂肪细胞分泌含有醛酮还原酶 1B7 的细胞外体,导致小鼠非酒精性脂肪性肝炎。
Free Radic Biol Med. 2021 Feb 1;163:220-233. doi: 10.1016/j.freeradbiomed.2020.12.011. Epub 2020 Dec 25.
4
Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans.TM6SF2 E167K对人类肝脏脂质及极低密度脂蛋白代谢的影响。
JCI Insight. 2020 Dec 17;5(24):144079. doi: 10.1172/jci.insight.144079.
5
Lipidomics in non-alcoholic fatty liver disease.非酒精性脂肪性肝病中的脂质组学
World J Hepatol. 2020 Aug 27;12(8):436-450. doi: 10.4254/wjh.v12.i8.436.
6
Disruption of the ERLIN-TM6SF2-APOB complex destabilizes APOB and contributes to non-alcoholic fatty liver disease.ERLIN-TM6SF2-APOB 复合物的破坏使 APOB 不稳定,并导致非酒精性脂肪性肝病。
PLoS Genet. 2020 Aug 10;16(8):e1008955. doi: 10.1371/journal.pgen.1008955. eCollection 2020 Aug.
7
Update on NAFLD genetics: From new variants to the clinic.非酒精性脂肪性肝病遗传学研究进展:从新的变异到临床应用。
J Hepatol. 2020 Jun;72(6):1196-1209. doi: 10.1016/j.jhep.2020.02.020. Epub 2020 Mar 4.
8
Nonalcoholic Fatty Liver Disease 2020: The State of the Disease.2020年非酒精性脂肪性肝病:疾病现状
Gastroenterology. 2020 May;158(7):1851-1864. doi: 10.1053/j.gastro.2020.01.052. Epub 2020 Feb 13.
9
The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids.TM6SF2 E167K 基因变异可诱导人肝 3D 球体中的脂质生物合成并降低载脂蛋白 B 的分泌。
Sci Rep. 2019 Aug 12;9(1):11585. doi: 10.1038/s41598-019-47737-w.
10
Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis.血清醛酮还原酶家族 1 成员 B10 可预测非酒精性脂肪性肝炎的晚期肝纤维化和致命并发症。
J Gastroenterol. 2019 Jun;54(6):549-557. doi: 10.1007/s00535-019-01551-3. Epub 2019 Feb 1.